Brind.

Cel-Sci filed securities with the SEC, with ThinkEquity acting as the sole placement agent.

5 reports, 1 independent Updated Aug 30
Gone quiet
Reports
5
Developments
1
Repetition
80%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Cel-Sci filed securities with the SEC, with ThinkEquity acting as the sole placement agent.

Who's involved

What this event is mainly about
Cel-Sci (United States)ThinkEquitySecurities and Exchange Commission

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireCEL-SCI Announces Closing of $10 Million Public Offering VIENNA, Va., August 29, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer
  • Business WireCEL-SCI Announces Proposed Public Offering VIENNA, Va., August 27, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy
  • Business WireCEL-SCI Announces Pricing of $10 Million Public Offering VIENNA, Va., August 28, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer
  • Business WireCEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules VIENNA, Va., July 14, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE A
  • Business WireCEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules VIENNA, Va., July 11, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE A